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Abstract
Among the age-related diseases, the development of cognitive impairments, in particular dementia, is the most
devastating for the individual and has great social and healthcare costs. Accurate information is needed about the
prevalence and incidence of cognitive disorders and the physiology of the ageing brain. In particular, only scant
data are available about the relationship between ageing, cognitive status and nutritional factors. In order to
address these issues we planned the Conselice Study of Brain Ageing, a longitudinal study of physiologic and
pathologic brain ageing. The center involved in the study was the municipality of Conselice, Ravenna province, in
the Northern Italian region Emilia-Romagna. A total of 1016 subjects aged 65 and over was enrolled at baseline.
Information about cognitive status at 4-years of follow-up was collected for 940 of them. These data have been
used to estimate prevalence and incidence of dementia in the elderly Italian population and to investigate the
possible role of baseline blood homocysteine as risk factors for dementia.
Introduction
Among the age-related diseases, dementia is the most
devastating for the individual and the one with the
greatest social and healthcare costs. Therefore, a better
understanding of potentially modifiable risk factors for
cognitive impairment of older age and early identifica-
tion of individuals at increased risk of dementia is a
high priority. The Conselice Study of Brain Ageing was
specifically planned to address the following specific
objects:
1) collection of epidemiologic information about the
prevalence and incidence of dementia in a sample repre-
sentative of the elderly Northern Italian population;
2) investigation of dementia risk factors, with particu-
lar focus on potentially reversible conditions such as
hyperhomocysteinemia;
3) creation of a large biomedical bank of data (includ-
ing lifestyle, nutritional, physical and cognitive status,
and laboratory values) and biological material available
for further multidisciplinary studies of ageing.
Design and methods of the conselice
study of brain ageing
The study was conducted by the Centre for the Study of
Fisiopathology of Ageing, University of Bologna, in
cooperation with the Conselice Municipality, the
Ravenna local health unit (Azienda Unità Sanitaria
Locale (A.U.S.L) of Ravenna, Italy) and Conselice gen-
eral practitioners.
Study population and sample size
The centre involved in the study is the municipality of
Conselice, in the Ravenna Province, Emilia Romagna
region. This municipality is representative of the Emilia
Romagna region in terms of geographic distribution,
sociodemographic, and life-style factors. It has a stable
population with a very low migration rate (less than
0.2% of people over 64 years had moved elsewhere in
the five years preceding the study). Conselice area was a
rural one, and only during the last two decades has
been transformed into an urban area, with middle to
high socio-economic status. However, elderly inhabitants
of this area were raised and lived in a rural environment
most of their life.
All the individuals aged 65 years and older who at
January 1, 1999, according to the municipal registry
office, were residing in Conselice were considered
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eligible individuals (75%) were evaluated: 453 men and
563 women, mean age 74.6 ± 7.1 years and with on
average 4.6 ± 2.4 years of education. Blood samples
were obtained from 985 participants. Refusers did not
significantly differ from participants for gender, age and
education. Between 2003-2004, 751 of the 864 survivors
of the baseline cohort were re-assessed. Moreover, infor-
mation adequate for a cognitive status diagnosis was
collected for 65 of the 113 refusers and 124 of the 152
individuals who deceased before follow-up.
All participants gave their written, informed consent.
The study protocol was approved by the local ethical
board.
Evaluation procedures
The same procedures and diagnostic tests were used at
baseline and at the follow-up examination. At each
examination, evaluation included two phases:
1) extensive screening of all participants in order to
characterize their actual biomedical, cognitive and socio-
functional status;
2) neuropsychological testing and neuroradiological
assessment for all suspect cases of cognitive impairment
identified at the screening phase in order to formulate a
final diagnosis of dementia.
The screening included a personal interview, a clinical
evaluation and fasting venous blood drawing:
a) Personal interview. A comprehensive standardized
questionnaire was administered to each subject includ-
ing information on socio-demographic characteristics,
lifestyle habits, medical history and current use of medi-
cations. Whenever available, medical records were
reviewed. If the subject was unable to answer because of
physical or mental impairments, information was
obtained from a proxy informant (relatives and the sub-
ject’s general pratictioner). Diagnoses were recorded
according to the International Classification of Diseases,
9th revision (ICD-9). The leisure time physical activity
assessment within the past year was done using the
Paffenbarger Physical Activity Questionnaire inter-
viewer-administered [1].
Subjects residing in institutions or unable to leave
their home were visited at their dwelling. For subjects
who did not participate to the follow-up examination,
telephone information about their cognitive and func-
tional status was sought. All deaths in the baseline
cohort during follow-up time were identied from the
municipality registry office. Information regarding cogni-
tive status in the last six months prior to death was col-
lected from all available sources (relatives, medical
charts, general pratictioners).
b) Clinical Evaluation. All participants underwent a
standardized and extensive medical examination also
including standardized anthropometric measurements,
the Tinetti test for mobility and balance, Basic and
Instrumental Activities of Daily Living, neuropsychologi-
cal screening using the Italian version of Folestein’s
Mini Mental State Examination (MMSE), the Clock
Drawing Test, and the Yesavage’s Geriatric Depression
Scale (see [2] for full details and references about the
instruments used for the assessment).
c) Venous blood drawing after an overnight fast. The
blood samples collected at baseline were partly used for
routine blood analysis (including full blood count, ESR,
glucose, lipids, renal, liver, and thyroid function, fibrino-
gen, CRP, folate, vitamin B12) and partly stored as
serum, plasma and DNA aliquots at -70°. Total homo-
cysteine was measured on frozen plasma sample by fully
automatized fluorescence polarization immunoassay (see
[3] for full details). Further neuropsychological evalua-
tion of the subjects with suspect cognitive impairment
at the screening phase was performed using the the
Mental Deterioration Battery [4] and scheduling a non-
contrast computed tomography brain scan for all sub-
jects with MMSE < 24/30. For persons scoring below
ten on the MMSE further neuropsychological testing
was not deemed necessary. The physicians responsible
for the neuropsychological examination discussed all
possible cognitive impairment cases with a senior physi-
cian and final diagnoses were made after reviewing all
available medical, laboratory, and neuroradiological data.
If additional information were needed, the patient’s gen-
eral pratictioner was contacted. Dementia was defined
by DSM IV criteria [5], Alzheimer’s disease (AD) by
NINCDS-ADRDA criteria [6] and Vascular Dementia
(VaD) by NINDS-AIREN criteria [7]. The diagnosis of
dementia was made only in subjects with duration of
cognitive decline of at least six months. Subjects affected
by major sensory or motory deficits, by severe depres-
sion (Geriatric Depression Scale score > 20), or by other
psychiatric disease hampering a reliable cognitive assess-
ment were deemed “cognitively unclassifiable”.
Prevalence and incidence of dementia in the
CSBA
Most of the current knowledge about of dementia epi-
demiology in Italy is based on prevalence data, which
show variations due to differences in case ascertainment
procedures, diagnostic criteria, and age distribution of
the population studied. Population-based longitudinal
studies provide the best estimate of the problem dimen-
sion as well as identification of risk and protective fac-
tors, but are expensive and time-consuming. Before the
conclusion of the CSBA first follow-up, the only avail-
able data on dementia incidence in Italy were those pro-
vided almost ten years ago by the Italian Longitudinal
Study of Aging (ILSA) [8], reporting an incidence rate
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1,000 person-years for Alzheimer Disease, and 3.3 per
1,000 person-years for vascular dementia (data standar-
dized to the 1995 Italian population).
Epidemiology of dementia in the CSBA cohort
Overall prevalence of dementia in the CSBA cohort, cal-
culated on the 1016 subjects who completed the proto-
col at baseline, was 5.9% (95%CI: 4.2 – 8.0) [9]. These
figures are similar to those from ILSA [8] and other
European population-based studies [10]. Our study con-
firmed AD as the most frequent type of dementia (50%
of all cases), whereas our prevalence rate for VaD (45%)
was almost doubled with respect to previous estimates
[11]. A possible methodologic explanation is that, differ-
ently from previous studies, our diagnoses of dementia
subtypes incorporate information from neuroradiologic
data, and NINDS-AIREN classification of VaD includes
cases of dementia resulting from brain infarcts as well
as from small-vessel disease. Another important finding
f r o mt h ep r e v a l e n c ep h a s eo fC S B Ai st h ea s s o c i a t i o n
found between education and dementia prevalence [9].
According to the “brain reserve hypothesis”, education
may provide a reserve of brain capacity able to compen-
sate for brain structural damages [12]. It may be tempt-
ing to hypothesize a reduction in dementia prevalence
as a result of the progress of education among western
populations. A number of methodological problems,
however, particularly culture-fair dementia diagnostic
procedures, need to be solved before research in this
area can generate reliable estimates.
According to data from the follow-up examination at
four-year of the CSBA cohort [13], incidence rates per
1,000 person-years were 37.8 (95% CI = 30.0 – 47.7) for
all-cause dementia, 23.8 (95% CI = 17.3 – 31.7) for AD,
and 11.0 (95% CI = 7.2 – 16.9) for VaD. These estimates
are substantially higher than those previously reported
in the ILSA cohort. Table 1 details incidence of demen-
tia and its subtypes by age group in the CSBA cohort
and also reports estimates for the expected number of
new cases in the Italian population as calculated from
national demographic projections for 2020 (ISTAT
2004). On the basis of CSBA data, in 2020 our country
might have to face about 584,000 new dementia cases
versus the 230,000 new cases predicted applying the
ILSA rates.
Homocysteine as a risk factor for cognitive
impairment and dementia
Homocysteine is a sulfur-aminoacid whose blood levels,
in elderly people are frequently increased because of
age, physiological decrease in renal function, and deficits
of B vitamins, mainly folate and vitamin B12 [14].
Homocysteine is currently recognized as a predictor of
vascular disease [15], but evidence is growing for its
possible role as a risk factor for dementia in the elderly
[16]. Mechanisms suggested for a causal role of hyper-
homocysteinemia in the etiopathogenesis of brain
damage are: vascular damage, impaired brain methyla-
tion reactions related to folate and vitamin B12 deficits,
and direct neurotoxic effects. Using data from the preva-
lence phase of the CSBA, we reported for the first time
that, in healthy non-demented elderly community-dwell-
ers, elevated plasma homocysteine has an independent,
graded association with concurrent cognitive impair-
ment as measured with the MMSE [3]. Moreover, in the
CSBA cohort, hyperhomocysteinemia (defined as plasma
tHcy > 15 μmol/L), was associated with an increasing
risk of developing dementia (HR 2.08, 95%CI 1.31-3.30)
and AD (HR 2.11, 95%CI 1.19-3.76) at follow-up [17].
Independently of hyperhomocysteinemia and other con-
founders, low folate levels were also associated with an
increased risk of both dementia and AD whereas no
association was found for vitamin B12. As shown in
Table 2, which reports risk of any dementia and AD
across quartiles of plasma tHCy and serum folate, the
associations exhibited a dose-effect trend. Our findings
cannot be used as a basis for treatment recommenda-
tions. However, they prompt realization of clinical trials
in humans aimed to verify whether interventions that
Table 1 Incidence rates of dementia in the Conselice
Study of Brain Aging and corresponding projections in
2020 for the Italian population
Age
Groups,
Years
Findings in 2003-2004
Rate per 1,000
person-years
Projection in 2020: No. of
expected new cases
in Italy
All
dementias
65 – 69 8.6 [3.9 – 19.2]
70 – 74 23.3 [15.2 – 35.9]
75 – 79 45.02 [32.2 – 63.0]
80 – 84 55.1 [36.7 – 83.0]
85 – 94 111.8 [78.7 – 159.0]
All ages 37.8 [30.0 – 47.7]* 584,575
Alzheimer’s
Disease
65 – 74 11.3 [7.1 – 17.9]
75 – 84 28.1 [20.0 – 39.6]
85 – 94 75.8 [49.4 – 116.2]
All ages 23.8 [17.3 – 31.7]* 378,310
Vascular
Dementia
65 – 74 5.0 [2.5 – 10.0]
75 – 84 16.2 [10.3 – 25.4]
85 – 94 25.2 [12.0 – 53.0]
All ages 11.0 [7.2 – 16.9]* 165,388
* standardized to the 2003 Italian population.
95% confidence interval in brackets.
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can lower the risk of dementia and AD in the Italian
population.
Other modifiable dementia risk factors identified
in the conselice study of brain ageing
The CSBA database is proving an invaluable resource for
investigations of other modifiable dementia risk factors
such as the antioxidant vitamin E. A study of the effect
of vitamin E status on dementia risk in this cohort [18]
did not confirm previous reports of a beneficial associa-
tion with plasma alpha-tocopherol, which is the most
abundant vitamin E form in the human body, the one
with the highest biological activity, and also the most
extensively investigated. However, a U-shaped associa-
tion, with lower risk for intermediate tertiles, was found
for incident dementia with g-tocopherol (Hazard ratio:
0.42; 95%CI: 0.22-0.84). The only investigation including
measuring of plasma g-tocopherol has a cross-sectional
design and reported no association of this tocopherol
form with concurrent cognitive performance [19]. By
contrast, the inverse association found in the CSBA
cohort between risk of incident dementia and plasma
g-tocopherol agrees with results from a study suggesting
that dietary g-tocopherol may have a protective role
against dementia [20]. Although a less powerful chain-
breaking antioxidant than a-tocopherol, g-tocopherol is
superior as a scavenger of reactive nitrogen species,
which are thought to significant contribute to neurode-
generative diseases via oxidative damage [21]. Addition-
ally, g-tocopherol has anti-inflammatory properties [22]
that may be important in dementia prevention. It is
not clear why, in our study, the beneficial effect of
g-tocopherol was evident only for the middle tertile. A
possible explanation is that higher g-tocopherol status
m a yb ea s s o c i a t e dw i t hu n h e a l t h yd i e t a r yb e h a v i o u r s ,
such as higher intakes of saturated and trans-unsaturated
fats [21].
Another relevant finding is the association between
VaD risk and physical activity [23]. Longitudinal investi-
gations of the effect of physical activity on dementia risk
in elderly persons are few in number and produced
inconsistent results. A lower risk of all-cause dementia
and Alzheimer’s dementia (AD) among subjects regu-
larly practising low-to-medium intensity physical activ-
ities was found in some population-based studies
[24-28] but not in others [29-32]. Moreover, only a few
investigations examined the effect of physical activity on
vascular dementia (VaD) risk [24,25,27,32] and none
reported an association.
Longitudinal investigations of the effect of physical
activity on dementia risk in elderly persons are fewer in
number and produced inconsistent results, especially as
far as VaD is concerned. In the CSBA cohort, VaD risk
was significantly lower for the upper tertiles of walking
(Hazard Ratio [HR] 0.27, 95%CI 0.12 to 0.63), moderate
(HR 0.29, 95%CI 0.12 to 0.66), and total physical activity
(HR 0.24, 95% 0.11 to 0.56) compared to the corre-
sponding lowest tertile. The association persisted after
accounting for vascular risk factors and overall health
status. The following, not mutually exclusive, hypotheses
have been proposed to explain how cognition may bene-
fit from physical activity [33,34]. First, physical activity
may improve cerebral blood flow and lower the risk of
cerebrovascular disease and. Second, physical activity
may stimulate synaptic plasticity, secretion of trophic
factors, neurotransmitter synthesis, and neurogenesis,
providing cognitive reserves against brain damage.
Third, physical activity may decrease secrection of
brain-toxic stress hormones like cortisol. Finally, more
than from exercise itself, the beneficial effects of physi-
cal activity on cognition might result, all or in part,
Table 2 Risk of any dementia and Alzheimer Disease by quartiles of plasma total homocysteine and serum folate
Any Dementia AD
HR [95% Confidence Interval] P value HR (95% Confidence Interval) P value
Quartiles of plasma total homocysteine, μmol/L
< 10.1 1.00 1.00
10.1 to 12.5 1.73 [0.87 – 3.46] 0.117 2.43 [0.96 – 6.13] 0.062
12.6 to 15.0 2.02 [0.96 – 4.23] 0.060 2.43 [0.96 – 6.13] 0.060
> 15.00 3.55 [1.72 – 7.29] 0.001 4.33 [1.73 – 10.8] 0.002
Quartiles of serum folate, nmol/L
< 8.9 2.22 [1.21 – 4.05] 0.010 2.04 [1.02 – 4.09] 0.045
8.9 to 11.8 1.83 [1.00 – 3.34] 0.050 1.30 [0.62 – 2.72] 0.484
11.9 to 15.2 1.16 [0.60 – 2.24] 0.064 0.66 [0.29 – 1.54] 0.340
> 15.2 1.00 1.00
Data are for 816 subjects; the number of incident dementia cases was 112 for any dementia and 70 for Alzheimer’s Disease (AD).
Hazard Ratios (HR) are adjusted for age, gender, education, APOE genotype, creatinine, serum levels of folate and vitamin B12, stroke, smoking status, diabetes,
hypertension, cardiovascular disease, and body-mass-index.
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active lifestyle. It is important to note that, in terms of
lowering VaD risk, an easy-to-perform moderate activity
like walking provided the same benefits of other, more
demanding activities of similar intensity, and being in
the upper tertiles of total weekly energy expenditure did
not offered any specific additional advantage. This find-
ing may be important for future studies attempting to
define strategies for prevention of cognitive impairment
in the elderly.
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